

CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

--

1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
CD40 agonistic antibody		BioxCel	BE0016-2	FGK4.5
Anti-PD-1				29F.1A12
CD8 depleting antibody		BioxCel	BE0061	2.43
YAP		Santa Cruz Biotechnology	Sc-101199	63.7
Anti-Cytokeratin 7		Abcam	Ab181598	ERP17078
Cytokeratin 19 monoclonal antibody		Abcam	Ab52625	EP1580Y
b-Actin		BioLegend	622101	Poly6221
Horseradish peroxidase secondary anti-mouse antibody		Cell Signalling Technology	7076S	
Iba1		Biocare	CP 290 A, B	N/A
CD11c		Cell Signaling	97585	D1V9Y
CD8a		eBioscience	14-0808-82	4SM15
PD-1		R&D Systems	8986-PD-100	
PD-L1		R&D Systems	156-B7	B7-H1
CD40		abcam	Ab47021	B-B20
Live/dead fixable near-IR		ThermoFischer	L34976	
Anti-CD3 BV605		BioLegend	100237	17A2
Anti-CD4 FITC		BioLegend	100509	RM4-5
anti-CD8 AF700		BioLegend	100729	53-6.7
Anti-NK1.1 BV510		BioLegend	108737	PK-136

Anti-CD69 BV421		BioLegend	104527	H1.2F3
Anti-OX40 PE		BioLegend	119409	OX-86
Anti-CD44 PE/Cy7		BioLegend	103029	1M7
Anti-CD62L PerCP/Cy5		BioLegend	104431	MEL-14
Anti-Tim3 BV421		BioLegend	119723	RMT3-23
Anti-CD3 PerCP/Cy5.5		BioLegend	100217	17A2
Anti-CD4 PE/Cy7		BioLegend	100421	GK1.5
Anti-PD1 FITC		BioLegend	135213	29F.1A12
Anti-LAG3 APC		BioLegend	125209	C9B7W
Anti-CD69 AF700		BioLegend	104539	H1.2F3
Anti-Foxp3 APC		eBioscience	17-5773-82	FJK-16s
Anti-T-bet PE/Cy7		BioLegend	644823	4B10
Anti-GATA3 PerCP/Cy5		BioLegend	653811	16E10A23
Anti-RORgt PE		eBioscience	12-6988-82	B20
Anti-CD4 AF700		BioLegend	100429	GK1.5
Anti-CD8 BV421		BioLegend	100737	53-6.7
Anti-IFNy APC		BioLegend	505809	XMG1.2
Anti-CD11b PB		BioLegend	101223	M1/70
Anti-CD11c BV650		BioLegend	117339	N418
Anti-F4/80 PE		eBioscience	123109	BM8
Anti-CD40 FITC		BioLegend	124607	3/23
Anti-MHCII(I-A- I-E) BV510		BioLegend	107635	M5/114.15.2
Anti-CD86 APC		BioLegend	105011	GL-1
Anti-CD107a PE		BD Biosciences	121611	1D4B
Anti-IFNy PE/Cy7		BioLegend	505825	505825

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
SB1		Yarchoan Lab (JHUSOM)			

1.3 Organisms

Updated version November 2018

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
C57BL/6 mice		Charles River Lab		female	8 weeks	72
Batf3 ^{-/-} mice		Jackson Lab				

1.4 Sequence based reagents

Name	Sequence	Supplier

1.5 Biological samples

Description	Source	Identifier

1.6 Deposited data

Name of repository	Identifier	Link

1.7 Software

Software name	Manufacturer	Version
GraphPad Prism 8		Version 8.3.0
HALOTM image analysis software	Indica Labs, Corales, NM	
Aperio AT2 digital whole slide scanner	Leica Biosystems, Buffalo Grove, IL	
Pattern recognition image analysis integrated software	Supervised machine learning	Random Forest classifier
R Studio	R Foundation for Statistical Computing, Austria, package "survival"	Version 1.2.5
CytoFLEX LX	Beckman Coulter	
FlowJo	TreeStar Inc.	Version 10.4.2
NanoDrop Spectrophotometer	ThermoFischer Scientific	
ViiATM7 real-time PCR system		
Chemiluminescence reagents	Clarity/Clarity Max ECL, BioRad	

1.8 Other (e.g. drugs, proteins, vectors etc.)

Gemcitabine	NIH Vet Pharmacy	
Cisplatin	NIH Vet Pharmacy	

Chemiluminescence reagents	ECL/ECL Plus - BioRad	
Paraformaldehyde	Fischer Scientific	
Foxp3/transcription factor staining buffer set	eBioscience	
Halt Protease and Phosphatase Inhibitor	Thermo Fischer Scientific	
BCA Protein Assay	Thermo Fischer Scientific	

1.9 Please provide the details of the corresponding methods author for the manuscript:

Tim Greten.
 Thoracic and GI Malignancy Section, TGMB NIH/NCI/CCR Building 10 Rm 2B28B
 9000 Rockville Pike, Bethesda MD 20892 USA
 Telephone: +1 (240) 760 6114
 E-mail: tim.greten@nih.gov

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

--